EHA26: J&J’s multiple myeloma therapies impress with new data

New data for Talvey and Tecvayli was presented at the annual meeting as J&J directs its therapies in earlier-line settings. New data for Talvey and Tecvayli was presented at the annual meeting as J&J directs its therapies in earlier-line settings. As the treatment landscape for R/R MM is rapidly evolving, GlobalData anticipates notable growth in the MM therapeutics market. Credit: PixelBiss/Shutterstock.com. Johnson & Johnson (J&J) has shared data from several studies evaluating two of its approved therapies in multiple myeloma (MM) at this year’s European Hematology Association (EHA) conference, held in Stockholm, Sweden on June 11–14. Both Talvey (talquetamab) and…

Source: Clinical Trials Arena